Table 1.

The patient TIL number used in each experiment. The experiments in each of Figures 1–8 are listed, together with the patient number from which the TILs were derived.

	Experiment	Patient # included
Figure 1	Phenotypic screening	10, 11, 15, 20
Figure 2	T-cell proliferation and differentiation
	(a) and (b): T-cell growth	8, 9. 10, 11. 20, 22
	(c): CTV measurements	11, 20
	(d) and (e): T-cell subtype	11
Figure 3	Transduction with CAR
	(a): CAR expression	10
	(b): CAR expression	11
	(c): CAR expression	8, 9, 10, 11, 15, 20, 22
	(d): #CAR per cell	10, 11, 15
Figure 4	Transduction maintained following REP	10
Figure 5	Melanoma tumor Her2 antigen expression
	(a): S100 B expression	10
	(b): S100 B expression	11
	(c): melanoma tumor Her2 antigen expression	10, 11, 34, 46
	(d): Melanoma sorted for High Her2 antigen expression	11, 15
	(e): melanoma tumor Her2 antigen expression	10, 11, 15, 34, 46
Figure 6	IFNγ production and cell killing
	(a)–(f): IFNγ production	11, 15, 20
	(g)–(i): cell killing	10, 11
Figure 7	Transduction with CAR and cell phenotype	10, 11
Figure 8	TIL activity in vivo	10

CAR, chimeric antigen receptor; CTV, cell trace violet; REP, rapid expansion protocol; TIL, tumor-infiltrating lymphocyte.